These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 3991621)
1. Methods of evaluating the alleged teratogenicity of environmental agents. Brent RL Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621 [No Abstract] [Full Text] [Related]
2. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
5. Methods for predicting human birth defects. Clayson DB Prog Clin Biol Res; 1985; 163C():197-203. PubMed ID: 3991622 [No Abstract] [Full Text] [Related]
6. Regulatory aspects of teratology: role of the Food and Drug Administration. Kelsey FO Teratology; 1982 Apr; 25(2):193-9. PubMed ID: 7048616 [TBL] [Abstract][Full Text] [Related]
7. Potential subversion of pregnancy prevention program in the managed care setting. Wilkin JK Arch Dermatol; 1997 Feb; 133(2):243-4. PubMed ID: 9041846 [No Abstract] [Full Text] [Related]
8. The importance of epidemiology in identifying drugs which may cause malformations--with particular reference to drugs containing sex hormones. Kelsey FO Acta Morphol Acad Sci Hung; 1980; 28(1-2):189-95. PubMed ID: 7004099 [No Abstract] [Full Text] [Related]
9. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Brinker A; Kornegay C; Nourjah P Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377 [TBL] [Abstract][Full Text] [Related]
10. Development and standardization of screening methods for behavioral teratology. Buelke-Sam J; Kimmel CA Teratology; 1979 Aug; 20(1):17-29. PubMed ID: 515959 [No Abstract] [Full Text] [Related]
11. Improper interpretation of data concerning teratogenicity: a case report. Staples RE Prog Clin Biol Res; 1985; 163C():161-3. PubMed ID: 3921981 [No Abstract] [Full Text] [Related]
12. Systematic identification of drugs that cause birth defects--a new opportunity. Mitchell AA N Engl J Med; 2003 Dec; 349(26):2556-9. PubMed ID: 14695418 [No Abstract] [Full Text] [Related]
13. Drugs in pregnancy and their effects on pre- and postnatal development. Kelsey FO Res Publ Assoc Res Nerv Ment Dis; 1973; 51():233-43. PubMed ID: 4590403 [No Abstract] [Full Text] [Related]
14. Pregnancy categories for prescription drugs. FDA Drug Bull; 1982 Dec; 12(3):24-5. PubMed ID: 7166220 [No Abstract] [Full Text] [Related]
15. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Nava-Ocampo AA; Koren G Clin Obstet Gynecol; 2007 Mar; 50(1):123-31. PubMed ID: 17304029 [TBL] [Abstract][Full Text] [Related]
16. Monitoring and avoiding drug and chemical teratogenicity. Koren G; MacLeod SM CMAJ; 1986 Nov; 135(10):1079-81. PubMed ID: 3094926 [No Abstract] [Full Text] [Related]
17. Drug and other hazards to the fetus and newborn. Freeman MM; Finkel MJ Prog Clin Biol Res; 1980; 36():67-72. PubMed ID: 7403181 [No Abstract] [Full Text] [Related]
18. The susceptibility of the fetus and child to chemical pollutants. Animal tests to screen for human teratogens. Sullivan FM Pediatrics; 1974 May; 53(5):822-3. PubMed ID: 4416518 [No Abstract] [Full Text] [Related]